Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (128)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
  7. Research Letter (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (287)
  2. Breast Medicine Service (287)
  3. Department of Medicine (287)
  4. GSK Faculty (287)
  5. Human Oncology and Pathogenesis Program (287)
  6. Solid Tumor Oncology Division (287)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (58)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (17)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix
    Journal Article

    Kim, S. H.; Basili, T.; Dopeso, H.; Da Cruz Paula, A.; Bi, R.; Issa Bhaloo, S.; Pareja, F.; Li, Q.; da Silva, E. M.; Zhu, Y.; more...
    Journal of Pathology (2022)

    Fulltext@MSK | Save
  • AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
    Journal Article

    Bardia, A.; Chandarlapaty, S.; Linden, H. M.; Ulaner, G. A.; Gosselin, A.; Cartot-Cotton, S.; Cohen, P.; Doroumian, S.; Paux, G.; Celanovic, M.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Accelerating drug development in breast cancer: New frontiers for ER inhibition
    Review

    Ferraro, E.; Walsh, E. M.; Tao, J. J.; Chandarlapaty, S.; Jhaveri, K.
    Cancer Treatment Reviews (2022)

    Fulltext@MSK | Save
  • The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation
    Journal Article

    Ladewig, E.; Michelini, F.; Jhaveri, K.; Castel, P.; Carmona, J.; Fairchild, L.; Zuniga, A. G.; Arruabarrena-Aristorena, A.; Cocco, E.; Blawski, R.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Androgen receptor splice variant-7 in breast cancer: Clinical and pathologic correlations
    Journal Article

    Ferguson, D. C.; Mata, D. A.; Tay, T. KY.; Traina, T. A.; Gucalp, A.; Chandarlapaty, S.; D'Alfonso, T. M.; Brogi, E.; Mullaney, K.; Ladanyi, M.; more...
    Modern Pathology (2022)

    Fulltext@MSK | Save
  • Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Journal Article

    Ferraro, E.; Singh, J.; Patil, S.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Barrio, A. V.; Malani, R.; Mellinghoff, I. K.; Boire, A.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors
    Journal Article

    Li, Q.; Jiang, B.; Guo, J.; Shao, H.; Del Priore, I. S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Neuroendocrine tumours of the breast: A genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites
    Journal Article

    Pareja, F.; Vahdatinia, M.; Marchio, C.; Lee, S. S. K.; Da Cruz Paula, A.; Derakhshan, F.; da Silva, E. M.; Selenica, P.; Dopeso, H.; Chandarlapaty, S.; more...
    Journal of Clinical Pathology (2022)

    Fulltext@MSK | Save
  • AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER-2) metastatic breast cancer (mBC)
    Meeting Abstract

    Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S. A. D. S.; Boni, V.; Gosselin, A.; Cartot-Cotton, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save